Hodges Capital Management Inc. Sells 7,057 Shares of AbbVie Inc. $ABBV

Hodges Capital Management Inc. cut its position in AbbVie Inc. (NYSE:ABBV) by 26.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 19,642 shares of the company’s stock after selling 7,057 shares during the period. Hodges Capital Management Inc.’s holdings in AbbVie were worth $4,943,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC boosted its holdings in shares of AbbVie by 17.4% in the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after acquiring an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC grew its position in AbbVie by 72.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after acquiring an additional 3,064 shares during the last quarter. Schnieders Capital Management LLC. increased its holdings in AbbVie by 5.0% during the 2nd quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock valued at $3,056,000 after purchasing an additional 789 shares in the last quarter. Ieq Capital LLC increased its holdings in AbbVie by 4.6% during the 2nd quarter. Ieq Capital LLC now owns 120,035 shares of the company’s stock valued at $22,281,000 after purchasing an additional 5,274 shares in the last quarter. Finally, Worldquant Millennium Advisors LLC raised its position in AbbVie by 117.3% in the 2nd quarter. Worldquant Millennium Advisors LLC now owns 1,135,034 shares of the company’s stock valued at $210,685,000 after purchasing an additional 612,702 shares during the last quarter. 70.23% of the stock is owned by institutional investors.

Insider Activity

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the transaction, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. The trade was a 30.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.06% of the stock is owned by company insiders.

AbbVie Stock Down 1.5%

Shares of AbbVie stock opened at $261.88 on Friday. The business has a fifty day simple moving average of $247.72 and a 200 day simple moving average of $227.22. The stock has a market cap of $462.69 billion, a PE ratio of 73.98, a price-to-earnings-growth ratio of 0.88 and a beta of 0.30. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $267.47.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The firm had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. During the same quarter in the prior year, the firm posted $2.97 earnings per share. The company’s quarterly revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Analysts expect that AbbVie Inc. will post 14.07 EPS for the current fiscal year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were issued a $1.73 dividend. The ex-dividend date was Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.6%. AbbVie’s dividend payout ratio (DPR) is 195.48%.

Wall Street Analysts Forecast Growth

A number of research firms have commented on ABBV. HSBC reissued a “buy” rating and issued a $300.00 price objective on shares of AbbVie in a research note on Monday, July 6th. Piper Sandler lifted their price target on AbbVie from $298.00 to $303.00 and gave the company an “overweight” rating in a report on Thursday. Wolfe Research upgraded shares of AbbVie from a “peer perform” rating to an “outperform” rating and set a $300.00 price target on the stock in a research report on Thursday, August 13th. Royal Bank Of Canada increased their price objective on shares of AbbVie from $260.00 to $280.00 and gave the stock an “outperform” rating in a report on Friday, July 10th. Finally, JPMorgan Chase & Co. raised their price objective on shares of AbbVie from $260.00 to $280.00 and gave the company an “overweight” rating in a research report on Thursday, July 9th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and a consensus target price of $275.95.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie reached a new 52-week high. The move above its previous July peak signals continued buying interest and reinforces the stock’s strong uptrend. ABBV is trading well above its 50-day and 200-day moving averages. AbbVie Hits a New 52-Week High
• Positive Sentiment: Analysts and dividend investors remain constructive on ABBV. AbbVie has gained about 19% in 2026, while its $1.73 quarterly dividend provides an annualized payout of $6.92 per share. Recent analyst views include buy ratings and price targets as high as $300, supporting the bullish case. Dividend Giants Pfizer, Chevron, AbbVie
• Positive Sentiment: AbbVie completed a $10 billion senior-notes offering to help fund its Apogee Therapeutics acquisition. The financing supports expansion of AbbVie’s immunology and specialty-medicine pipeline, potentially helping offset future pressure from Humira competition. AbbVie Completes Senior Notes Offering
• Neutral Sentiment: AbbVie paid €370 million in Irish corporation tax last year. The disclosure highlights the company’s significant Irish operations but is unlikely to materially change near-term earnings expectations. AbbVie Irish Corporation Tax
• Negative Sentiment: Executive Vice President Nicholas Donoghoe sold 32,710 ABBV shares for approximately $8.18 million. The transaction reduced his direct holdings by about 30.5%. Although it may reflect personal financial planning, the sizable sale can weigh modestly on sentiment, particularly after the stock’s strong rally. AbbVie Insider Selling
• Negative Sentiment: The Apogee acquisition financing increases AbbVie’s leverage. Investors will evaluate higher interest costs and whether Apogee’s pipeline can generate sufficient returns. ABBV also trades at a high earnings multiple, leaving less room for disappointing results.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.